Should GLP-1 agonists should be used earlier in type 2 diabetes?
In the future, GLP-1 agonists could be used early in treatment for type II diabetes and this could have an important impact on slowing the onset of complications, […]
In the future, GLP-1 agonists could be used early in treatment for type II diabetes and this could have an important impact on slowing the onset of complications, […]
GLP-1 agonists such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents are now […]
One promising approach to treating Type 1 diabetes is implanting pancreatic islet cells that can produce insulin when needed, which can free patients from giving themselves frequent insulin […]
Persons with an evening ‘chronotype”’ (going to bed late and waking up late), have a 19 percent increased risk of diabetes compared to those with a morning chronotype, […]
A simple blood test may predict the risk of progressive heart and kidney disease in people with Type 2 diabetes and kidney disease, according to new research published today in […]
People with type-II diabetes who drank the fermented tea drink kombucha for four weeks had lower fasting blood glucose levels compared to when they consumed a similar-tasting placebo […]
On 27th June 2023 NHS England issued a Medicine Supply Notification (MSN/2023/061) concerning GLP-1 receptor agonists (GLP-1 RAs) used for management of type 2 diabetes. This action has […]
More than half a billion people are living with diabetes worldwide, affecting men, women, and children of all ages in every country, and that number is projected to […]
People who develop diabetes following pregnancy were significantly less likely to be able to bring it under control if they had experienced gestational diabetes during their pregnancy, especially […]
A research team led by the Complexity Science Hub Vienna and the Medical University of Vienna has analysed the actual prevalence of Type 2 diabetes in Austria for […]
In a small feasibility study, subjects with type 2 diabetes achieved significant improvement in long-term blood sugar levels following treatment with high-dose tadalafil, an erectile dysfunction drug. Tadalafil […]
Alex Miras is Professor of Endocrinology at the University of Ulster, UK and is an expert in obesity management and research. In 2021 a trial of semaglutide for […]
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.
